TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer.

Jordan, Weston; Wildfang, I.; Welkoborsky, H.-J.; Borghardt, J.; Zakaria, Hazli; Fanaei, S.; Niebuhr, H.; Luft, S; Tschechne, B.

doi:10.1200/jco.2010.28.15_suppl.5514

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jordan et al57 treated 152 SCCHN patients with T3 or T4 tumors with three 3-week cycles of TPF (docetaxel 75 mg/m 2 on day 1, cisplatin 35 mg/m 2 on days 1 and 2, and 5-FU 750 mg/m 2 /day, as a continuous infusion on days 1–5, with pegfilgrastim support) followed by CRT (63 Gy in 35 fractions of 1.8 Gy over 7 weeks and weekly cisplatin, 40 mg/m 2 ) plus weekly cetuximab. The complete response rate in the 142 patients who were evaluated after the completion of therapy was 57%.…”

Section: Efficacy Studies Including Any Comparative Studiesmentioning

confidence: 99%

Cetuximab: its unique place in head and neck cancer treatment

Specenier¹,

Vermorken²

2013

BTT

View full text Add to dashboard Cite

Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed each year. The epidermal growth factor receptor (EGFR) is almost invariably expressed in SCCHN. Overexpression of the EGFR is a strong and independent unfavorable prognostic factor in SCCHN. Cetuximab is a chimeric monoclonal antibody, which binds with high affinity to the extracellular domain of the human EGFR, blocking ligand binding, resulting in inhibition of the receptor function. It also targets cytotoxic immune effector cells towards EGFR-expressing tumor cells (antibody dependent cell-mediated cytotoxicity). The addition of cetuximab to radiotherapy (RT) improves locoregional control and survival when compared to RT alone. The addition of cetuximab to platinum-based chemoradiation (CRT) is feasible but does not lead to an improved outcome. Cetuximab plus RT has never been compared prospectively to CRT, which therefore remains the standard treatment for patients with locoregionally advanced SCCHN for whom surgery is not considered the optimal treatment, provided they can tolerate CRT. The addition of cetuximab to platinum-based chemotherapy prolongs survival in patients with recurrent or metastatic SCCHN. The combination of a platinum-based regimen and cetuximab should be considered as the standard first line regimen for patients who can tolerate this treatment.

show abstract

Section: Efficacy Studies Including Any Comparative Studiesmentioning

confidence: 99%

Cetuximab: its unique place in head and neck cancer treatment

Specenier¹,

Vermorken²

2013

BTT

View full text Add to dashboard Cite

show abstract

“…A local recurrence occurred in 17.5% of the patients. Jordan et al [ 22 ] treated 152 T3-T4 SCCHN patients with three 3-week cycles of TPF (docetaxel 75 mg/m² on day 1, cisplatin 35 mg/m² on days 1 and 2, and 5-FU 750 mg/m²/day, as a continuous infusion, days 1–5, with pegfilgrastim support) followed by chemoradiation (63 Gy in 35 fractions of 1.8 Gy over 7 weeks and weekly cisplatin, 40 mg/m²) plus weekly cetuximab. The complete response rate in the 142 patients, who were evaluated after the completion of therapy, was 57%.…”

Section: Egfr-directed Therapiesmentioning

confidence: 99%

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Specenier

Vermorken

2012

ISRN Oncology

View full text Add to dashboard Cite

The epidermal growth factor receptor (EGFR) is overexpressed in the vast majority of cases of squamous cell carcinoma of the head and neck (SCCHN). A high EGFR expression is associated with an unfavorable prognosis. Cetuximab is a chimeric human/murine IgG1 antibody which binds with high affinity to the EGFR. It is the only targeted agent which got approval for the treatment of SCCHN from the regulatory agencies of Europe and the United States, both in locoregionally advanced disease, in association with radiation, and in recurrent/metastatic disease. The outcome of trials involving other EGFR-directed monoclonal antibodies, that is, zalutumumab and panitumumab, was consistent with the results with cetuximab. However these trials failed to meet their primary endpoint. The results with EGFR-directed tyrosine kinase inhibitors have been disappointing. Other potential targets for treatment in SCCHN include the entire ErbB family, the vascular endothelial growth factor (VEGF) and its receptor (VEGFR), the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (IR), histone deacetylases (HDAC), the mammalian target of rapamycin (mTOR), the platelet-derived growth factor receptor (PDGFR), heat-shock protein 90 (HSP90), nuclear factor-kappa B (NF-κB), aurora A or B, and phosphatidylinositol 3-kinase (PIK3CA).

show abstract

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Fujisawa

2014

Int J Clin Oncol

View full text Add to dashboard Cite

The multidisciplinary approach is becoming the standard for treatment of advanced head and neck cancer. Combined modality treatment preserves quality of life as well as improving the length of survival time. Molecular targeted drugs have become very important in the multidisciplinary approach for the treatment of advanced head and neck cancer. Cetuximab has been shown to have locoregional control and additional survival benefits in locally advanced squamous cell carcinoma of the head and neck as well as additional survival benefits in distant metastatic/recurrent squamous cell carcinoma of the head and neck. Recently, many clinical studies of the multidisciplinary approach including cetuximab have been carried out in Europe and the US. It has been shown that cetuximab in combination with radiotherapy (RT) is significantly superior to the RT alone in median locoregional control duration and median overall survival (OS). For recurrent or metastatic disease, the results of a phase III randomized control study of CDDP + 5-fluorouracil combination therapy with or without cetuximab reported that OS was significantly longer with than without cetuximab, demonstrating an additional survival benefit of cetuximab. Many trials including induction chemotherapy are being conducted. Clinical trials with cetuximab have also been conducted in Japan. Though combination with cetuximab shows some benefit, further studies are necessary to obtain the standard treatments for a multidisciplinary approach for advanced head and neck cancer.

show abstract

TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer.

Cited by 5 publications

References 0 publications

Cetuximab: its unique place in head and neck cancer treatment

Cetuximab: its unique place in head and neck cancer treatment

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Contact Info

Product

Resources

About